AbbVie's Upside Potential Limited in Pipeline-Light 2026, BofA Securities Says
Bank of America (BofA) Securities has lowered its price target for AbbVie (ABBV) stock to $233 from the previous $248, while maintaining a Neutral rating due to the perceived limitation of upside potential from a "pipeline-light" 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.